Few studies have examined the decision-making process for selecting a mood stabilizer or antipsychotic for patients with bipolar disorder. Despite a lack of evidence regarding their efficacy, conventional unimodal antidepressants continue to be used in bipolar treatment regimens. This article examines pharmacologic principles that can facilitate the evidence-based use of mood stabilizers and antipsychotics in patients with bipolar disorder. Choosing therapies for the maintenance of bipolar disorder, clinical decision making upon observation of a partial response, the use of combination therapies, and benefit/harm considerations when choosing a treatment for bipolar depression will be reviewed.
From the Department of Psychiatry, George Washington University School of Medicine, Washington, DC, and the Bipolar Collaborative Network, Bethesda, Maryland (Dr Post); the Bipolar Disorder and Depression Research Program, Veterans Affairs Palo Alto Health Care System, and the Department of Psychiatry and Behavioral Sciences; Stanford University School of Medicine, Palo Alto, California (Dr Ostacher); and the Department of Psychiatry and the University Hospital Psychiatric Service, University of Texas Health Science Center at San Antonio (Dr Singh).
Find more articles on this and other psychiatry and CNS topics:
The Journal of Clinical Psychiatry
The Primary Care Companion for CNS Disorders
Free Access: Please Log In
This content is completely free—but you need to be logged in to read the full article. If you already have an account, please log in below. Otherwise, register for free to unlock instant access.